NCT05861362View on ClinicalTrials.gov

Feasibility and Metabolic Effects of a 5:2 Fasting Intervention in Women With Breast Cancer During Radiotherapy

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

November 17, 2022

Study Completion Date

November 17, 2022

Conditions
Breast Cancer
Interventions
RADIATION

Curative radiotherapy

Curative radiotherapy as indicated by the patient's disease and prescribed by the treating radiation oncologist

BEHAVIORAL

5:2 intermittent fasting

Two nonconsecutive days of fasting per week that could be chosen freely according to the patient's weekly schedule.

Trial Locations (2)

97421

Department of Radiotherapy and Radiation Oncology, Schweinfurt

Leopoldina Hospital Schweinfurt, Department of Radiotherapy and Radiation Oncology, Schweinfurt

All Listed Sponsors
lead

MVZ Leopoldina GmbH

OTHER

NCT05861362 - Feasibility and Metabolic Effects of a 5:2 Fasting Intervention in Women With Breast Cancer During Radiotherapy | Biotech Hunter | Biotech Hunter